Stack AI
AI agents that interact and answer questions with users and complete tasks using your data and APIs. AI that can answer questions, summarize and extract insights from any long document. Transfer styles and formats, as well as tags and summaries between documents and data sources. Stack AI is used by developer teams to automate customer service, process documents, qualify leads, and search libraries of data. With a single button, you can try multiple LLM architectures and prompts. Collect data, run fine-tuning tasks and build the optimal LLM to fit your product. We host your workflows in APIs, so that your users have access to AI instantly. Compare the fine-tuning services of different LLM providers.
Learn more
MuukTest
You know that you could be testing more to catch bugs earlier, but QA testing can take a lot of time, effort and resources to do it right. MuukTest can get growing engineering teams up to 95% coverage of end-to-end tests in just 3 months.
Our QA experts create, manage, maintain, and update E2E tests on the MuukTest Platform for your web, API, and mobile apps at record speed. We begin exploratory and negative tests after achieving 100% regression coverage within 8 weeks to uncover bugs and increase coverage. The time you spend on development is reduced by managing your testing frameworks, scripts, libraries and maintenance.
We also proactively identify flaky tests and false test results to ensure the accuracy of your tests. Early and frequent testing allows you to detect errors in the early stages your development lifecycle. This reduces the burden of technical debt later on.
Learn more
Volpara Health
Volpara Health software is utilized by various facilities, including leading cancer screening centers in the United States, to facilitate the early detection of breast cancer. Mammography technologists depend on this software to enhance the quality of mammograms. Recognized as the most scientifically validated screening tool in the breast health sector, Volpara provides essential evidence at critical moments. It offers access to comprehensive patient data, enabling more accurate assessments of breast cancer risk. Each analyzed image contributes to refining our algorithms for early detection of the disease. Your support is crucial in promoting additional screening or genetic tests for patients. The platform allows for the creation of tailored worklists and reports according to individual preferences. Users can simultaneously view statistics and lists from a single interface, making the process more efficient. Communication can be standardized across patients, referrers, and insurers, ensuring clarity and consistency. Furthermore, it enhances the delivery of result letters by incorporating thumbnail images of mammograms, making the information more engaging and informative. This multifaceted approach ultimately promotes better patient care and outcomes in breast health.
Learn more
The Galen Platform
Ibex Medical Analytics stands at the forefront of AI-driven cancer diagnostics within the field of pathology. Our diverse team comprises entrepreneurs, data scientists, software engineers, and medical professionals united in our mission to revolutionize cancer diagnostics through artificial intelligence, ultimately enhancing patient care. As the volume of tests continues to rise annually, pathologists face significant challenges in delivering precise and timely analyses. To address this, Ibex harnesses the power of AI to create clinical-grade solutions that aim to identify cancer with the same level of accuracy as a human pathologist. The Galen Platform employs advanced algorithms to scrutinize images, detect and classify cancer in biopsy samples, and highlight other clinically significant findings, thereby assisting pathologists in minimizing diagnostic errors while streamlining their workflow. Notably, Ibex’s Galen™ Prostate and Galen™ Breast solutions represent the pioneering AI-based cancer detection tools integrated into routine clinical practice in pathology labs, showcasing proven efficacy in uncovering previously missed cancer cases. As we continue to innovate, our commitment to improving cancer detection and patient outcomes remains unwavering.
Learn more